SOAR Trial, A Two-part Study: Interventional Phase II Single-arm Trial to Assess Efficacy and Safety of Eltrombopag Combined With Cyclosporine as First Line Therapy in Patients With Severe Acquired Aplastic Anemia, and an Extension With up to 60-months Follow-up
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Jul 2017
At a glance
- Drugs Ciclosporin (Primary) ; Eltrombopag (Primary)
- Indications Aplastic anaemia
- Focus Therapeutic Use
- Acronyms SOAR
- Sponsors Novartis Pharmaceuticals
- 10 May 2017 Planned End Date changed from 10 Jul 2023 to 11 Jul 2023.
- 10 May 2017 Planned primary completion date changed from 10 Jul 2023 to 11 Jul 2023.
- 10 May 2017 Planned initiation date changed from 10 Apr 2017 to 19 May 2017.